FDA Submission Update for Sugammadex by Tamarang SA
Tamarang SA has submitted an original ANDA for Sugammadex, currently under standard review.
Published: July 14, 2026
Updated: July 14, 2026
Author: Humanexa Intelligence
Therapeutic area: Anesthesia / Neuromuscular Blockade
Asset: Sugammadex
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Sugammadex
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The submission of an ANDA for Sugammadex by Tamarang SA represents a significant regulatory event that could alter the competitive landscape in the neuromuscular blockade market. Approval could lead to increased competition, impacting pricing and market share for existing products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the review progress and any updates on approval status from the FDA.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.